CeriBell (NASDAQ:CBLL) Stock: Insider Joseph Michael Taylor Sells 10,200 Shares

Key Points

• Director Joseph Michael Taylor sold 10,200 CeriBell shares at an average $27.22, totaling $277,644. He retained 38,278 shares after reducing his stake by 21.04%.
• CeriBell reported quarterly revenue of $29.34 million, slightly above estimates, but its loss of $0.55 per share was wider than the expected $0.51 loss.
• Analysts’ consensus rating is Moderate Buy, with a $31.25 average price target; shares recently traded at $27.48.

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Joseph Taylor sold 10,200 shares of the company's stock in a transaction on Monday, November 9th. The stock was sold at an average price of $27.22, for a total transaction of $277,644.00. Following the completion of the transaction, the director owned 38,278 shares of the company's stock, valued at $1,041,927.16. This trade represents a 21.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Joseph Michael Taylor also recently made the following trade(s):

• On Thursday, August 13th, Joseph Taylor sold 13,095 shares of CeriBell stock. The shares were sold at an average price of $23.40, for a total value of $306,423.00.

CeriBell Price Performance

NASDAQ CBLL traded down $0.12 during trading hours on Tuesday, reaching $27.48. 327,271 shares of the stock traded hands, compared to its average volume of 373,306. The company has a debt-to-equity ratio of 0.17, a current ratio of 8.18 and a quick ratio of 8.79. The stock has a 50 day simple moving average of $25.33 and a two-hundred day simple moving average of $20.95. CeriBell, Inc. has a 1 year low of $11.75 and a 1 year high of $28.89. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -14.16 and a beta of 0.86.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). CeriBell had a negative return on equity of 52.59% and a negative net margin of 67.96%. The firm had revenue of $29.34 million during the quarter, compared to analysts' expectations of $29.18 million. On average, analysts predict that CeriBell, Inc. will post -2.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CBLL has been the subject of several recent research reports. Raymond James Financial reissued a "strong-buy" rating and set a $29.00 price objective on shares of CeriBell in a research report on Thursday, September 3rd. Barclays raised shares of CeriBell to a "neutral" rating in a research report on Tuesday, August 18th. TD Cowen increased their price target on shares of CeriBell from $29.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday, October 2nd. Canaccord Genuity Group lifted their price target on shares of CeriBell from $26.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, November 4th. Finally, BTIG Research reissued a "buy" rating on shares of CeriBell in a research note on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.25.

Institutional Investors Weigh In On CeriBell

Several hedge funds have recently added to or reduced their stakes in CBLL. Strs Ohio bought a new position in shares of CeriBell during the first quarter valued at $27,000. Legal & General Group Plc purchased a new stake in CeriBell during the 2nd quarter valued at about $53,000. State of Wyoming bought a new stake in CeriBell during the 1st quarter valued at about $62,000. Quantbot Technologies LP bought a new stake in CeriBell during the 2nd quarter valued at about $112,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in CeriBell in the first quarter worth about $341,000.

CeriBell Company Profile

Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company's Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.